Wednesday, September 23, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Long-Term Data Updated At Transplant Conference. Eledon presented an update to the Phase 2 BESTOW Extension study at the International Congress of The Transplantation Society. Analysis up to 24 months after transplantation showed that patients treated with tegoprubart had statistically significant improvements in kidney function compared with patients treated with tacrolimus. Separately, tegoprubart has also received Fast Track designation from the FDA in the kidney transplant indication.
Updated Extension Study Data. Patients completing the BESTOW trial were entered into an Extension Stage to follow outcomes after the trial period ended. At 18, 21, and 24 months, tegoprubart patients had a higher eGFR of about 71 mL/min/1.73m2 compared with 58 mL/min/1.73m2 for tacrolimus, with differences that were statistically significant. Tegoprubart patients showed a continued improvement in eGFR after the trial, while tacrolimus patients showed a gradual but steady decline.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
